Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.

Area of Science:

• Cardiovascular Biology
• Renal Disease Pathophysiology
• Molecular Medicine

Background:

• Vascular calcification is common in end-stage renal disease and linked to poor outcomes.
• Poly(ADP-ribose) polymerase 1 (PARP1) inhibition shows protective effects in various disease models.

Purpose of the Study:

• To investigate the role of PARP1 in vascular calcification associated with chronic renal failure.
• To elucidate the molecular mechanisms by which PARP1 influences vascular smooth muscle cell phenotype and mineralization.

Main Methods:

• Assessed PARP activity in human and rat arteries and in vitro vascular smooth muscle cells (VSMCs).
• Examined the effects of PARP1 deficiency and overexpression on VSMC transdifferentiation and calcification.
• Investigated the regulatory pathway involving PARP1, IL-6/STAT3, miRNA-204, and Runx2.

Main Results:

• PARP activity was elevated in chronic renal failure patients, uraemic rats, and calcified VSMCs.
• PARP1 deficiency inhibited, while overexpression exacerbated, VSMC osteogenic transdifferentiation and calcification.
• PARP1 promotes Runx2 expression, partly by suppressing miRNA-204 via the IL-6/STAT3 pathway.

Conclusions:

• PARP1 plays a protective role against vascular calcification.
• The PARP1-miRNA-204-Runx2 axis is a key regulator of vascular smooth muscle cell calcification.
• Modulating PARP1 activity presents a potential therapeutic avenue for vascular calcification.